Search
Miltefosine
go.drugbank.com/drugs/DB09031ApprovedInvestigationalThe CDC has also recommended it as a first line treatment for free-living amebae (FLA) infections such as primary amebic meningoencephalitis and granulomatous amebic encephalitis. … Miltefosine is a broad spectrum antimicrobial, anti-leishmanial, phospholipid drug that was originally developed in the 1980s as an anti-cancer agent.
Etoposide
go.drugbank.com/drugs/DB00773ApprovedInvestigationalAccumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. … A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA.
Categories: UGT1A1 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexProducts: INJECTION ETOPOSIDE CS 100MG IN 5MLGolodirsen
go.drugbank.com/drugs/DB15593ApprovedInvestigational[A188580,T756] A similar drug used in the treatment of other types of DMD is [eteplirsen], which targets a different genetic mutation. … [L10773] Golodirsen was developed by Sarepta Therapeutics and granted accelerated FDA approval on December 12, 2019 due to the urgent need for this drug in patients suffering from a certain form of
Categories: Compounds used in a research, industrial, or household settingNafcillin
go.drugbank.com/drugs/DB00607ApprovedInvestigationalIt may be used as a first-line therapy in Methicillin-Sensitive *Staphylococcus aureus* infections [A20360]. … A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug.
Cefroxadine
go.drugbank.com/drugs/DB11367ApprovedWithdrawnIt was used in Italy but has since been withdrawn. … Cefroxadine is an orally available cephalosporin antibiotic. As part of its drug class, it shares structural properties to [cefalexin] as well as its activity spectrum.
Nivolumab
go.drugbank.com/drugs/DB09035ApprovedInvestigationalNivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). … [L12129] Nivolumab was granted FDA approval on 22 December 2014.[L12129] It is also available in combination with [relatlimab] under the brand name Opdualag.[L41265,L49996,L50001]
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsD-alpha-Tocopherol acetate
go.drugbank.com/drugs/DB14002ApprovedNutraceuticalVet approvedMoreover, RRR-alpha-tocopherol acetate is a relatively stabilized form of vitamin E that is most commonly used as a food additive when needed [A32451]. … Vitamin E itself is naturally found in various foods, added to others, or used in commercially available products as a dietary supplement.
Mixtures: Vitamin A C E W.niacinam.beta Car.and Min., Escavite LqCategories: Compounds used in a research, industrial, or household setting, Vitamin ELutetium Lu 177 dotatate
go.drugbank.com/drugs/DB13985ApprovedInvestigationalPatients with GEP-NETs have limited second-line treatment options after the metastasis of tumors and inadequate therapeutic response from first-line therapies. … In a clinical trial involving patients with advanced somatostatin receptor-positive GEP-NET, the treatment of Lutetium Lu 177 dotatate in combination with octreotide resulted in longer progression-free
Synonyms: Lu-DOTATATE, [177]Lu-DOTA-TATECategories: Compounds used in a research, industrial, or household settingIdursulfase
go.drugbank.com/drugs/DB01271ApprovedInvestigationalIdursulfase is a purified form of human iduronate-2-sulfatase, a lysosomal enzyme. Idursulfase is produced by recombinant DNA technology in a human cell line. … The enzyme activity of idursulfase is dependent on the post-translational modification of a specific cysteine to formylglycine.
Synonyms: Alpha-L-iduronate sulfate sulfataseDaclatasvir
go.drugbank.com/drugs/DB09102ApprovedInvestigationalWithdrawnThe same dosing regimen can be used as first-line therapy in patients with genotype 3 without cirrhosis and second-line therapy in genotype 3 patients with compensated cirrhosis. … According to 2017 American Association for the Study of Liver Diseases (AASLD), 60mg of daclatasvir is recommended with 400mg [DB08934] for genotype 1a/b patients with or without cirrhosis as second-line